Latest news with #2025AnnualConference
Business Wire
3 days ago
- Business
- Business Wire
Deluxe Merchant Services Wins National Call Center Award of Distinction for 13th Consecutive Year
MINNEAPOLIS--(BUSINESS WIRE)--Deluxe (NYSE: DLX), a trusted Payments and Data company, has received the 2025 Association of TeleServices International (ATSI) Call Center Award of Distinction, recognizing the exceptional performance of the Deluxe Merchant Services customer care team. This marks the 13th consecutive year Deluxe has earned this national honor. Presented at ATSI's 2025 Annual Conference in Phoenix, AZ, the Award of Distinction is used to evaluate professional call center agents across North America and the UK over a six-month period, with independent judges scoring teams on real-world call scenarios that require complex problem-solving and high-quality customer care. 'Being recognized 13 years in a row by ATSI underscores the extraordinary work of our customer service professionals, who bring skill, patience, and a deep commitment to our clients every day,' said Brian Mahony, President of Merchant Services at Deluxe. 'Customer support is not just a function—it's a strategic advantage that helps drive success for the thousands of businesses we serve.' Deluxe Merchant Services is a complete payment processing solution that supports a wide range of payment methods, simplifies PCI compliance, and ensures a seamless checkout experience. Its U.S.-based support team operates 24/7 via phone, email, and chat, maintaining an industry-leading average tenure of 36 months among front-line agents. On average, the team fields approximately 15,000 calls per month and continues to improve service benchmarks year over year. ATSI's judging panel evaluates call centers on key criteria, including: Customer Relationship Management (CRM) Capabilities Courtesy to Caller Overall Professionalism Use of Proper Call Techniques Response Times Accuracy of Call 'The ATSI Award of Distinction was created to celebrate the agents who handle the most complex and high-stakes calls—those requiring advanced customer care, patience, and problem-solving,' said ATSI President Brianna Burke. 'It's more than a recognition—it's a statement that your team leads with quality, even when the call gets tough.' Now in its 24th year, the ATSI Award of Distinction continues to elevate the standards of the call center industry by measuring sophisticated call-handling practices and rewarding organizations that lead with empathy, skill, and professionalism. About Deluxe Corporation Deluxe, a trusted Payments and Data company, champions business so communities thrive. Our solutions help businesses pay, get paid, and grow. For more than 100 years, Deluxe customers have relied on our solutions and platforms at all stages of their lifecycle, from start-up to maturity. Our powerful scale supports millions of small businesses, thousands of vital financial institutions and hundreds of the world's largest consumer brands, while processing more than $2 trillion in annual payment volume. Our reach, scale and distribution channels position Deluxe to be our customers' most trusted business partner. To learn how we can help your business, visit us at
Axios
04-08-2025
- Business
- Axios
Why economic developers chose Detroit for their biggest gathering
When the International Economic Development Council (IEDC) picked a location for its 2025 Annual Conference, it was about proof, not convenience — and Detroit is a living case study that economic development works. The Motor City has transformed into a dynamic ecosystem where cutting-edge startups thrive alongside manufacturing plants, blending expertise across sectors to revitalize an iconic community. What you need to know: IEDC is the world's largest non-profit, non-partisan membership org dedicated to economic development, and its members serve across sectors from government and chambers of commerce to public-private partnerships and academia. 📆 The 2025 Annual Conference will be held Sept. 14—17 with a focus on the theme "Catalyzing Opportunity, Vitality and Prosperity." 🧠 Attendees will learn from local success models in the Motor City and hear both national and international expert takes. Why it's important: Economic development is a community health catalyst — when successful, it revitalizes neighborhoods, brings new jobs, increases public revenues, and strengthens social fabrics. Okay, but: The landscape is shifting, forcing economic developers to adapt to address urgent community needs like housing, workforce development, and childcare, while using data to inform their strategies and measure their impact. IEDC's Annual Conference is a chance for smart pros to head home with new tools, insights, and partnerships to help their communities develop resilience for the future. What IEDC is saying: Energy is building ahead of the conference. "I know that the people they bring in and the content they bring in will always be of the highest quality," ACC Capital Foundation Executive Director Tiffany Henry said. "As the profession and expectations on economic development grow and change, we need to continue to learn, innovate, and challenge traditional ideas to remain a thought leader," IEDC President and CEO Nathan Ohle said. What's in store: This isn't your typical professional development conference. Attendees will: Choose from curated tracks on topics like small business ecosystems, workforce transformation, cross-border collaboration, and capital access. Tour Detroit's revitalized corridors and see the impact of local public-private partnerships. Build peer networks that spark long-term collaboration. Participate in interactive sessions, case study presentations, and behind-the-scenes insights into Detroit's story as a model for community transformation. The takeaway: Detroit's transformation shows what's possible when bold strategies meet long-term investment — and IEDC's 2025 Annual Conference gives attendees the tools they need to do the same back home:
Business Wire
25-06-2025
- Business
- Business Wire
Euna Solutions Helps Governments Create Accessible, Award-Ready Digital ACFRs
ATLANTA & TORONTO--(BUSINESS WIRE)-- Euna Solutions ®, a leading provider of purpose-built SaaS solutions for the public sector, now enables governments to create digital ACFRs using its advanced reporting capabilities within Euna Budget. This new capability will be unveiled at the upcoming Government Finance Officers Association (GFOA) 2025 Annual Conference. Live demonstrations will take place at Booth #621, where Euna will showcase how agencies can streamline the production of accessible, GFOA award-aligned financial reports with integrated data and flexible reporting tools. 'Public sector finance teams are being asked to deliver clearer, more accessible annual reports while managing growing complexity,' said Tom Amburgey, CEO of Euna Solutions. 'Our financial reporting capabilities help agencies simplify reporting..." Share 'Public sector finance teams are being asked to deliver clearer, more accessible annual reports while managing growing complexity,' said Tom Amburgey, CEO of Euna Solutions. 'Our financial reporting capabilities help agencies simplify reporting, improve transparency, and deliver award-ready reports without adding technical burdens or resource strain.' Euna's publishing and reporting capabilities simplify the creation of a digital ACFR and empower finance teams to meet today's priorities for accessibility, accuracy, and transparency — while also helping agencies stay positioned for evolving federal reporting standards such as the Financial Data Transparency Act (FDTA). Offered to both new and existing customers, the new feature is designed for local governments, utilities, and special districts seeking to modernize their financial reporting processes. Key capabilities include: Compliance confidence: Produce reports that meet GFOA award requirements and align with GASB standards using built-in templates and smart checklists. Inclusive by design: Ensure full accessibility with ADA, ACA, and WCAG-compliant output. Data-driven accuracy: Leverage up-to-date data from Euna Budget to ensure consistency, improve accuracy, and eliminate redundant data entry. Flexible reporting: Create financial statements using advanced reporting functionality that supports custom layouts and dynamic formatting, and reduces manual edits to streamline report creation. Version mastery: Simplify ongoing updates and publishing by eliminating version control issues and enabling teams to easily republish corrected or updated reports. Full visibility: Present financial data in a clear, easy-to-navigate digital format that enhances transparency for stakeholders, auditors, funders, and the public. The solution integrates seamlessly into Euna Budget and is part of OpenBook, Euna's transparency solution. It extends the company's broader financial transparency and reporting capabilities, allowing agencies to share digital-first ACFRs while retaining the option to export and print for formal submissions or internal documentation. While the federal Financial Data Transparency Act (FDTA) continues to evolve, these digital ACFR capabilities are designed with future standards in mind, helping agencies stay aligned with evolving federal requirements while focusing on today's immediate priorities for accessibility, accuracy, and transparency. 'This solution meets agencies where they are today and helps position them for what's ahead,' added Amburgey. "Finance teams can focus on delivering clear, transparent financial information to their communities to ultimately increase public trust and reinforce the value of taxpayer dollars." To learn more about Euna Budget's ACFR capability, visit the Euna Solutions booth at GFOA 2025 Booth #621 for a live demo or visit About Euna Solutions Euna Solutions ® is a leading provider of purpose-built, cloud-based software that helps public sector and government organizations streamline procurement, budgeting, payments, grants management, and special education administration. Designed to enhance efficiency, collaboration, and compliance, Euna Solutions supports more than 3,400 organizations across North America in building trust, enabling transparency, and driving community impact. Recognized on Government Technology's GovTech 100 list, Euna Solutions is committed to advancing public sector progress through innovative SaaS solutions. To learn more, visit
Yahoo
24-06-2025
- Business
- Yahoo
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Four-year data show preservation of cardiac function, including LVEF Skeletal muscle disease progression continues to slow with extended treatment (PUL v2.0) Deramiocel's long-term safety profile remains favorable Results presented at PPMD's 2025 Annual Conference SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be featured in the session titled 'Therapies that Slow Progression' at the Parent Project Muscular Dystrophy (PPMD) 2025 Annual Conference, taking place June 21, 2025, in Las Vegas, Nevada. After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline. Further, a subgroup analysis of patients with baseline LVEF >45% showed an even greater clinical benefit, supporting early intervention with Deramiocel to potentially preserve cardiac function. Additionally, treatment continued to slow skeletal muscle disease progression, as measured by Performance of the Upper Limb (PUL v2.0), with patients experiencing a smaller average decline in the fourth year (0.6 points) compared to the first year (1.8 points). Together, these findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time. Deramiocel continues to maintain a favorable safety profile throughout the study. 'Cardiomyopathy remains one of the leading causes of mortality in Duchenne and addressing this aspect of the disease is critical to improving outcomes,' said Pat Furlong, Founding President and CEO of PPMD. 'The long-term data from the HOPE-2 OLE study are encouraging, particularly in demonstrating cardiac stabilization over four years. Deramiocel represents an important therapeutic approach and we support continued progress through the regulatory pathway to ensure that treatments targeting both heart and muscle function are available to our community as quickly as possible.' 'These four-year data reinforce the strength and durability of Deramiocel's clinical benefit and favorable safety profile across both cardiac and skeletal muscle function,' said Linda Marbán, Ph.D., CEO of Capricor Therapeutics. 'With our BLA under priority review and several key regulatory steps now completed, we are executing with focus and urgency as we move toward potential approval. Our continued dialogue with the FDA remains on track with no evidence of any delays. We thank the patients, families, and clinicians who have been instrumental in advancing this program.' The PPMD Annual Conference is the largest international event focused on advancing research, clinical trials, and standards of care for Duchenne and Becker muscular dystrophies. Capricor's presentation will be available following the conference in the publications section of the Company's was a randomized, double-blind, placebo-controlled Phase 2 study of Deramiocel in boys and young men with Duchenne Muscular Dystrophy (DMD). Patients received intravenous infusions of either Deramiocel (150 million cells) or placebo every three months. The results were published in The Lancet. Following study completion, all patients entered a treatment gap phase for approximately 392 days (range: 239–567). Eligible patients then enrolled in the HOPE-2 OLE study, receiving Deramiocel every three months. The OLE study previously met its primary endpoint at one year with statistically significant improvement on the PUL v2.0 (p=0.02). Now in its fifth year, the HOPE-2 OLE study remains ongoing, with participants continuing to be monitored for safety, cardiac function, and upper limb Muscular Dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD. There is no cure, and treatment options remain (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert potent immunomodulatory and anti-fibrotic actions in the preservation of cardiac and skeletal muscle function in dystrophiopathies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing, rather than a pro-inflammatory phenotype. CDCs have been investigated in more than 250 peer-reviewed scientific publications and administered to over 250 human subjects across multiple clinical trials. Deramiocel has received Orphan Drug Designation for the treatment of Duchenne Muscular Dystrophy (DMD) from both the U.S. FDA and the European Medicines Agency (EMA). In addition, it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., Advanced Therapy Medicinal Product (ATMP) designation in Europe, and Rare Pediatric Disease Designation from the FDA, which may qualify Capricor for a Priority Review Voucher upon approval. For Becker Muscular Dystrophy (BMD), Deramiocel has also received Orphan Drug Designation from the Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown Deramiocel to exert potent immunomodulatory and anti-fibrotic actions in the preservation of cardiac and skeletal muscle function in muscular dystrophies such as DMD. Deramiocel is currently in late-stage development for the treatment of Duchenne Muscular Dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit and follow Capricor on Facebook, Instagram and in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'believes,' 'plans,' 'could,' 'anticipates,' 'expects,' 'estimates,' 'should,' 'target,' 'will,' 'would' and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the Securities and Exchange Commission on May 14, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements. Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug (IND) and is not yet approved for any indications. Neither BMD nor any of Capricor's exosome-based candidates have been approved for clinical Media Contact:Raquel ConaKCSA Strategic Communications rcona@ Capricor Company Contact:AJ Bergmann, Chief Financial Officerabergmann@
Daily Express
21-06-2025
- Politics
- Daily Express
Only Sabahans know state's woes: Masidi
Published on: Saturday, June 21, 2025 Published on: Sat, Jun 21, 2025 By: Clarence Dol Text Size: Masidi, PGRS leaders and supporters at the event. RANAU: The people of Sabah must give full support to the Gabungan Rakyat Sabah (GRS) government because only local leadership understands the real needs of the state as well as the people here. Sabah Parti Gagasan Rakyat Sabah (PGRS) Deputy President and Karanaan PGRS Division Head Datuk Seri Masidi Manjun said, as the state election looming, a new mandate must be given to the coalition in order to keep the prosperity going. Masidi highlighted the GRS government's achievements over the past 3 years despite various challenges. He noted that during the Covid-19 pandemic in September 2020, movement restrictions significantly impacted operations, but the government still managed to function effectively for nearly 4 years. He emphasized that the GRS government's achievements in 2 to 3 years were among the best in Sabah's history. Key accomplishments included increased government revenue, record-breaking public savings, and nearly triple the reserves compared to previous administrations. Advertisement Masidi who is also Sabah's Finance Minister was speaking when officiating the 2025 Annual Conference of the PGRS for the Kundasang, Karanaan and Paginatan Divisions that was held at the Dewan Masyarakat Ranau on Thursday. Regarding infrastructure, particularly water management, Masidi also addressed issues concerning electricity, roads and clean water supplies. He reminded the people that Sabah Electricity is not entirely under the state government, but it is more under the federal's Tenaga Nasional Berhad (TNB). In regards to the road problem, he said that such problems have also existed during the previous administrations, but today more road network and upgrading has been done, despite not being noticed by the oppositions. Concerning water issues, he explained that previous administration's decisions to terminate water management contracts led to current problems and legal claims totalling around RM300 million in compensation. He announced new developments, including a water treatment plant in Ranau from the Nakamura River that will provide consistent water supply regardless of weather conditions. Towards that end, Masidi emphasized the importance of political stability and professional governance for continued progress. The conference concluded with a call for unity within the party and focus on selecting capable candidates for upcoming elections. He stressed that elections are not beauty contests but rather about choosing hardworking individuals who can drive progress. Also present were PGRS Vice President Datuk Masiung Banah, Assistant Minister to the Chief Minister Datuk Abidin Madingkir, Ranau Member of Parliament Datuk Jonathan Yasin, Assemblyman-Elect Datuk Hjh Amisah Yassin and others. * Follow us on our official WhatsApp channel and Telegram for breaking news alerts and key updates! * Do you have access to the Daily Express e-paper and online exclusive news? Check out subscription plans available. Stay up-to-date by following Daily Express's Telegram channel. Daily Express Malaysia
